Cargando…

The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome

At present, prognostic biomarkers of acute coronary syndrome (ACS) are fewer. The aim of this study was to explore the predictive value of soluble osteoclast-associated receptor (sOSCAR) level for the major adverse cardiovascular events (MACE) occurring within 30 days after ACS. From January to Augu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rong, Wang, Jing, Xie, Ling, Cai, Hong-li, Zhang, Yi, Zhang, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169834/
https://www.ncbi.nlm.nih.gov/pubmed/34075158
http://dx.doi.org/10.1038/s41598-021-91054-0
_version_ 1783702109065052160
author Wang, Rong
Wang, Jing
Xie, Ling
Cai, Hong-li
Zhang, Yi
Zhang, Qing
author_facet Wang, Rong
Wang, Jing
Xie, Ling
Cai, Hong-li
Zhang, Yi
Zhang, Qing
author_sort Wang, Rong
collection PubMed
description At present, prognostic biomarkers of acute coronary syndrome (ACS) are fewer. The aim of this study was to explore the predictive value of soluble osteoclast-associated receptor (sOSCAR) level for the major adverse cardiovascular events (MACE) occurring within 30 days after ACS. From January to August 2020, a total of 108 patients with ACS who were admitted to our hospital, were enrolled in this study. Of the 108 patients, 79 were men and 29 women. Patient-related data, including age, sex, body mass index, history of type 2 diabetes, history of hyperlipidemia and serum sOSCAR level, were collected. All patients were followed up for 30 days. Based on MACE occurrence, the 108 patients were divided into MACE group (n = 17) and non-MACE group (n = 91). The baseline data were compared between the two groups, MACE-independent risk factors were identified by multivariate regression analysis, and the predictive value of sOSCAR for MACE occurring within 30 days after CAS was analyzed using receiver operating characteristic (ROC) curve. At the same time, according to the type of ACS, the 108 patients with ACS were divided into unstable angina (UA) group (n = 29), non ST-segment elevation myocardial infarction (USTEMI) group (n = 45) and ST-segment elevation myocardial infarction (STEMI) group (n = 34), and then the sOSCAR level and MACE incidence were observed in each group. The serum sOSCAR level was significantly lower in the MACE group [130(100,183)] than in the non-MACE group [301(220,370)] (P = 0.000). The area under ROC curve of sOSCAR level for MACE occurring within 30 days after CAS was 0.860 with 95%CI 0.782–0.919, P < 0.001. Multivariate regression analysis indicated that the sOSCAR level was an independent risk factor for the MACE occurring within 30 days after CAS (OR 0.26, 95%CI 0.087–0.777, P = 0.04). The MACE incidence (0%) was the lowest but the sOSCAR level was the highest in the UA group, while in the STEMI group, the MACE incidence (23.53%) was the higest but the sOSCAR level was the lowest among the UA, STEMI and NSTEMI groups. Serum sOSCAR level may be used as a predictor of MACE occurring within the short-term after ACS. The higher the sOSCAR level, the lower the MACE incidence.
format Online
Article
Text
id pubmed-8169834
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-81698342021-06-03 The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome Wang, Rong Wang, Jing Xie, Ling Cai, Hong-li Zhang, Yi Zhang, Qing Sci Rep Article At present, prognostic biomarkers of acute coronary syndrome (ACS) are fewer. The aim of this study was to explore the predictive value of soluble osteoclast-associated receptor (sOSCAR) level for the major adverse cardiovascular events (MACE) occurring within 30 days after ACS. From January to August 2020, a total of 108 patients with ACS who were admitted to our hospital, were enrolled in this study. Of the 108 patients, 79 were men and 29 women. Patient-related data, including age, sex, body mass index, history of type 2 diabetes, history of hyperlipidemia and serum sOSCAR level, were collected. All patients were followed up for 30 days. Based on MACE occurrence, the 108 patients were divided into MACE group (n = 17) and non-MACE group (n = 91). The baseline data were compared between the two groups, MACE-independent risk factors were identified by multivariate regression analysis, and the predictive value of sOSCAR for MACE occurring within 30 days after CAS was analyzed using receiver operating characteristic (ROC) curve. At the same time, according to the type of ACS, the 108 patients with ACS were divided into unstable angina (UA) group (n = 29), non ST-segment elevation myocardial infarction (USTEMI) group (n = 45) and ST-segment elevation myocardial infarction (STEMI) group (n = 34), and then the sOSCAR level and MACE incidence were observed in each group. The serum sOSCAR level was significantly lower in the MACE group [130(100,183)] than in the non-MACE group [301(220,370)] (P = 0.000). The area under ROC curve of sOSCAR level for MACE occurring within 30 days after CAS was 0.860 with 95%CI 0.782–0.919, P < 0.001. Multivariate regression analysis indicated that the sOSCAR level was an independent risk factor for the MACE occurring within 30 days after CAS (OR 0.26, 95%CI 0.087–0.777, P = 0.04). The MACE incidence (0%) was the lowest but the sOSCAR level was the highest in the UA group, while in the STEMI group, the MACE incidence (23.53%) was the higest but the sOSCAR level was the lowest among the UA, STEMI and NSTEMI groups. Serum sOSCAR level may be used as a predictor of MACE occurring within the short-term after ACS. The higher the sOSCAR level, the lower the MACE incidence. Nature Publishing Group UK 2021-06-01 /pmc/articles/PMC8169834/ /pubmed/34075158 http://dx.doi.org/10.1038/s41598-021-91054-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Rong
Wang, Jing
Xie, Ling
Cai, Hong-li
Zhang, Yi
Zhang, Qing
The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title_full The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title_fullStr The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title_full_unstemmed The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title_short The predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
title_sort predictive value of soluble osteoclast-associated receptor for the prognosis of acute coronary syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169834/
https://www.ncbi.nlm.nih.gov/pubmed/34075158
http://dx.doi.org/10.1038/s41598-021-91054-0
work_keys_str_mv AT wangrong thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT wangjing thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT xieling thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT caihongli thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT zhangyi thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT zhangqing thepredictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT wangrong predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT wangjing predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT xieling predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT caihongli predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT zhangyi predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome
AT zhangqing predictivevalueofsolubleosteoclastassociatedreceptorfortheprognosisofacutecoronarysyndrome